finanzen.net

KeryX Bio kann ein ErfolgsRebound werden !

Seite 4 von 5
neuester Beitrag: 11.06.10 12:49
eröffnet am: 21.03.08 17:11 von: Superflach Anzahl Beiträge: 124
neuester Beitrag: 11.06.10 12:49 von: lamaro Leser gesamt: 19548
davon Heute: 3
bewertet mit 4 Sternen

Seite: 1 | 2 | 3 |
| 5  

12.05.08 18:14

1026 Postings, 4432 Tage D23011964wann sehen wir .....

wieder die Kurse um die 0,60$ Marke? Wäre nicht schlecht wenn es Heute mind. bei 0,52 bleibt...
-----------
chris_crazy

19.05.08 23:34

1026 Postings, 4432 Tage D23011964Morgen...

sollten wir wieder ins Plus drehen. Da hat einer zum Schluß richtig zugelegt (vielleicht auch Inseider?) - fast einviertel der gekauften Aktien am Tag - auf einen Schlag:
http://de.advfn.com/...X&s_ok=OK&s_symbol_select=AMEX%3ALNG&minimise=
-----------
chris_crazy

22.05.08 22:43

1026 Postings, 4432 Tage D23011964ein interessanter Link...

http://www.smallcapinvestor.com/quotes/news

findet man auch auf der Homepage aktuelle 10 Q und andere interessante Sachen
-----------
chris_crazy

27.08.08 21:26

4155 Postings, 5364 Tage martin30sm20% Plus und keinem interessiert es....

28.08.08 15:59

4155 Postings, 5364 Tage martin30smwas ist hier los?

Schon 0,57 Dollar!  

05.11.08 20:54

4155 Postings, 5364 Tage martin30sm100% Plus heute!

Gewaltige Umsätze!
was gibt es Neues???  

06.11.08 18:39

4155 Postings, 5364 Tage martin30smAnscheinend bin ich der Einzige, der investiert

ist!

Wieder +30%, tolle Umsätze!  

07.11.08 13:22

21051 Postings, 4582 Tage Chalifmann3Keryx ???

Hallo Martin30,

Sag mal ,wie bist du aus atherogenics rausgekommen,oder bist du noch drin ? Dieser superflachinvestor ist ja schon beinahe ein Garant für totalverlust! Keryx jedenfalls hat über 90 Mio.-$ Miese gemacht,eine ende mit Schrecken,so wie bei Atherogenics ist auch hier denkbar,was meinst du ..?

MFG
Chali  

07.11.08 13:50

730 Postings, 5050 Tage OttomanRosendahlschaut euch doch Oramed an, ist nur ein Vergleich


zu den Werten, die alle irgendwie mit Insulin zu tun haben oder besser gesagt mit Diabetis Lösung zu tun haben ; )

Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)  

07.11.08 14:59

4155 Postings, 5364 Tage martin30sm@Chalifmann3

Bei Atherogenics habe ich bei 0,11 Dollar die Notbremse gezogen (Verlust von ca. 70%). Bei Keryx bin ich schon ein 3/4 Jahr drinnen, allerdings "nur" mit 8000 Stk. (KK: 0,55 Dollar).

Mich würde der Grund des Anstieges der letzten 2 Tage brennend interessieren, find leider nichts.

Dass Keryx die 2. Atherogenics wird glaube ich allerdings nicht.

Lg
Martin  

07.11.08 15:11

21051 Postings, 4582 Tage Chalifmann3Da

...gibts keinen speziellen bzw. spezifischen Grund,da bin ich mir ziemlich sicher,denn der Anstieg der letzten 2 Tage (das waren extrem schlechte Börsentage) hat auch andere zerbombte Biotechs nach oben gespült,z.b.- Cell Genesys,ist von 4 Dollar runter auf 0,09 (!!) und steht jetzt bei 0,36 Dollar. Apropos,diese Cell Genesys hatten immer eine sehr hohe Reputation,kennst du den Grund des Absturzes ? Die sind jedenfalls ähnlich hoch verschuldet wie es Atherogenics war ....

MFG
Chali  

07.11.08 16:22

4155 Postings, 5364 Tage martin30smDen Grund des Absturzes kenne ich leider nicht

07.11.08 16:54

21051 Postings, 4582 Tage Chalifmann3Keryx

.... dreht jedenfalls wieder nach unten und ist heute gleich mal fett in den Miesen. Ich entscheide viel nach "Bauchgefühl" und genau das warnt mich vor Keryx,aber frag mich nicht warum .....

MFG
Chali

P.S. Willst du noch in KERX aufstocken,falls es nochmal bis 0,10 Dollar runtergeht ?  

07.11.08 17:40

4155 Postings, 5364 Tage martin30smNein, nachkaufen tue ich nicht mehr!

Zur Zeit gibt es sicher einige andere Werte wo sich eine Investition mehr lohnt.

Bist du eigentlich drinnen in Keryx bzw. Atherogenics?  

07.11.08 20:11

21051 Postings, 4582 Tage Chalifmann3@martin

Ich war fett in Agix drin,bis zu der News,wo es um die Nichtbedienung der gläubiger ging.Das hatte mich so verärgert,dass ich bei 0,35 komplett raus war. Du hast übrigens BM von mir,in den in der BM nicht näher benannten Wert werde ich einsteigen,ansonsten bin ich nur noch in Cimatron drin. In Kerxy bin und war ich nie drin,viel glück !!

MFG
Chali  

09.12.08 20:48

5662 Postings, 4440 Tage _bbb_News

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hem
Date : 12/09/2008 @ 11:47AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
Quote :  0.2275  0.0775 (51.67%) @ 2:29PM


Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hem




Dr. Paul Richardson presents combined results from a Phase 1/2 study of perifosine in combination with bortezomib (+/- dexamethasone) in multiple myeloma patients relapsed from or refractory to bortezomib

NEW YORK, Dec. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced data on the clinical activity of perifosine (KRX-0401) in combination with bortezomib (+/- dexamethasone) in patients with relapsed/refractory multiple myeloma. The data was presented earlier today at the 50th annual meeting of the American Society of Hematology in an oral presentation by Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI).

The study entitled "A Multicenter Phase 1/2 Study Evaluating the Safety and Efficacy of Perifosine (KRX-0401) + Bortezomib (VELCADE(R)) in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma Who Were Previously Treated with Bortezomib," has completed enrollment with 84 patients, of which 24 remain on active treatment. In his presentation, Dr. Richardson presented results from the study as follows:

Trial Summary:

Eighty-four patients were enrolled in a combined Phase 1/2 study (18 patients in the Phase I component and 66 patients in the Phase II component). Median prior lines of therapy was 5 (range 1 - 13), including; 100% of patients had been treated with bortezomib (50% of the patients were previously treated with at least two bortezomib-based therapies and 81% were previously treated with bortezomib plus dexamethasone); 98% of patients were previously treated with dexamethasone; 98% of patients were previously treated with lenalidomide (Revlimid(R)) and/or thalidomide (Thalomid(R)); and 57% of patients had prior stem cell transplant. No unexpected adverse events have been seen. Toxicities were manageable with supportive care and/or dose reductions as required.

Overall Response Rate (ORR) which includes a minor response (MR) or better was the primary endpoint with Time to Progression (TTP) as a secondary endpoint. At the time of the presentation, 72 patients were evaluable for response. Evaluable patients were defined as those who had received at least two cycles of therapy on the combination of perifosine with bortezomib. Approximately 50% (35 / 72) of patients demonstrated progression at some point in their treatment and 20 mg dexamethasone (4 times per week) was added. Best response to either perifosine + bortezomib (+/-dexamethasone) for all 72 evaluable patients was as follows:

Evaluable Patients CR/nCR PR MR ORR SD** Perifosine + Bortezomib 72 2 3% 10 14% 5 7% 17 24% 16 30% With dex added* 35 1 1% 2 3% 7 10% 10 14% 13 11% Best Response n=72 3 4% 12 17% 12 17% 27 38% 29 40%

* as a subset of the evaluable population **SD = greater than or equal to 4 cycles


Median TTP for all study patients was 6.3 months. Median TTP for responding patients has not yet been reached, currently it is 8.8 months and on-going.

Particularly noteworthy was 52 (72%) of the evaluable patients were previously refractory (defined as progression on or within 60 days of treatment) to a bortezomib-based regimen, including 83% who were also refractory to the combination of bortezomib + dexamethasone. Response data for this bortezomib-refractory group was as follows:

VELCADE(R) Refractory CR/nCR PR MR ORR SD** Perifosine + Bortezomib 52 1 2% 4 8% 3 6% 8 15% 12 23% With dex added* 28 0 0% 2 4% 6 12% 8 15% 11 21% Best Response N=52 1 2% 6 12% 9 17% 16 31% 23 44%

(* as a subset of the evaluable population) **SD = greater than or equal to 4 cycles


Median TTP for all bortezomib-refractory patients was 6.2 months. Median TTP for responding patients has not yet been reached, currently it is 9.4 months and on-going.

Commenting on the data, Dr. Paul Richardson stated, "Perifosine appears to be particularly active with durable responses when combined with bortezomib and dexamethasone in a heavily pre-treated patient population. The encouraging response rate, impressive time to progression and manageable toxicity are especially favorable. We thus look forward to pursuing this combination in a randomized phase 3 trial."

Dr. Kenneth Anderson, Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) added, "We are excited at the results presented today as this data further confirms our early pre-clinical data demonstrating perifosine's ability to shut down bortezomib-activated AKT, which may help overcome bortezomib resistance."

Michael S. Weiss, Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, commented, "We are grateful for the dedication and diligence of the team of multiple myeloma investigators, led by Dr. Paul Richardson and Dr. Kenneth Anderson, who have rapidly translated pre-clinical findings into clinical results. In this heavily pre-treated patient population, the majority of whom had failed prior bortezomib-based therapy, we believe we have demonstrated that perifosine is an active, novel agent with the potential to provide clinical benefit to patients with multiple myeloma. We believe this data supports moving Perifosine into a phase 3 program and we are currently exploring the design of a randomized phase 3 placebo controlled clinical trial."

Two additional clinical posters were presented as follows:

Abstract 3691: Phase 1 Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM)

Thirty of 32 patients enrolled were evaluable for response. Perifosine in combination with Revlimid(R) + dexamethasone achieved a 70% ORR (MR or greater), with 50% of patients achieving at least a partial response (PR). The median progression-free survival (PFS) for the 21 patients (70%) who achieved at least an MR is 10.9 months as of November 2008 (not reached). Twenty-three of the 30 evaluable patients are still alive and the median overall survival has not been reached at 16.8 months. Ten patients remain on active treatment.

Abstract 1010: Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom's Macroglobulinemia (WM)

Single agent perifosine achieved a 36% ORR (MR, PR) and 58% stable disease in a heavily pre-treated Waldenstrom's Macroglobulinemia patient population. Clinical benefit was demonstrated as reflected by a median time to progression of 10.7 months.

KRX-0401 (Perifosine) Mechanism of Action and Profile

KRX-0401 (Perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key signal transduction pathways, including the JNK and MAPK pathways, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of perifosine on Akt are of particular interest because of the importance of this pathway in the development of most cancers, the evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis in patients with soft-tissue sarcoma, gastric, hepatocellular, endometrial, prostate, renal cell, head and neck cancers and hematological malignancies, as well as glioblastoma. The majority of tumors expressing high levels of pAkt were high-grade, advanced stage or had other features associated with poor prognosis. High pAkt is often seen in tumors that are resistant to conventional cancer treatments, including radiotherapy, chemotherapy, endocrine therapy, and especially therapy with some of the newer biologicals.

To date, over 1,700 patients have been treated with KRX-0401 in trials conducted both in the United States and Europe. Its safety profile is distinctly different from that of most cytotoxic agents. It does not appear to cause myelosuppression (depression of the immune system that may lead to life threatening infections), thrombocytopenia (a decrease in platelets that may result in bleeding), skin rash, flu-like symptoms or alopecia (hair loss); all of these toxicities occur frequently with many of the currently available treatments for cancer. The main side effects of perifosine are nausea, vomiting, diarrhea and fatigue, but these are either mild or non-existent in lower doses that have induced tumor regression. Responses have been seen with both daily and weekly regimens. At the doses studied, the daily regimens were better tolerated.

In Phase 1/2 trials, KRX-0401 has induced tumor regressions and/or caused disease stabilization in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocellular carcinoma, soft tissue sarcoma, GIST tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Disease stabilization, defined as time on treatment without progression for at least 6 months has been seen in 20 tumor types, including metastatic renal cell cancer, hepatocellular carcinoma, melanoma, carcinoid, prostate, head and neck, breast, and small cell lung cancer. Responding patients, including stable disease, have been treated for various durations up to more than three years.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris, Inc. (Nasdaq: AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com/. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT: Lauren Fischer Director - Investor Relations Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965 E-mail:

DATASOURCE: Keryx Biopharmaceuticals, Inc.


CONTACT: Lauren Fischer, Director, Investor Relations of Keryx

Biopharmaceuticals, Inc., +1-212-531-5965,


Web Site: http://www.keryx.com/  

23.01.09 16:53

3 Postings, 4014 Tage TouwseLöschung


Moderation
Moderator: neemax
Zeitpunkt: 23.01.09 17:35
Aktion: Löschung des Beitrages
Kommentar: Bashversuch

 

 

29.01.09 18:27

3 Postings, 4014 Tage TouwseStufe 3 erfolglos

Beim letzten Beitrag hatte ich wohl etwas zu viel geschrieben, daher hier nun die überarbeitete Fassung:

Gemäß der Credite Suisse ist die Phase III von Keryx gescheitert ( Info vom 22.1.09 )

Gruß....Touwse

 

08.05.09 19:59

4155 Postings, 5364 Tage martin30smWeiß jemand was mit Keryx los ist?

Starker Anstieg unter hohen Umsätzen!  

08.05.09 20:02

2613 Postings, 4981 Tage kiwi03ich glaube....

momentan steigt alles was nur irgendwie pharmaceutical oder ähnlich im namen stehen hat. scheinen momentan in mode zu sein die titel.  

01.06.09 11:38

1364 Postings, 4060 Tage tomixjetzt kommt grad noch n Schub.

krass wie die abgeht :o)  

01.06.09 19:20

221 Postings, 4294 Tage Nickname76Bin

mal wieder drin, war vor einiger Zeit mal investiert. Was meint Ihr wie sich KERX nach der positiven Phase weiter entwickeln wird?  

02.06.09 10:21

26242 Postings, 4342 Tage brunnetaHeute ist Gewinnmitnahme angesagt

-----------
Keine Kauf Empfehlung!!
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen"

02.06.09 10:26

1649 Postings, 4639 Tage AndreanoGlückwunsch Jungs

von 0,09 USD auf 1,40 USD wow  

Seite: 1 | 2 | 3 |
| 5  
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Daimler AG710000
NEL ASAA0B733
Aurora Cannabis IncA12GS7
Deutsche Bank AG514000
TeslaA1CX3T
Ballard Power Inc.A0RENB
Microsoft Corp.870747
thyssenkrupp AG750000
Apple Inc.865985
EVOTEC SE566480
CommerzbankCBK100
Amazon906866
BASFBASF11
Allianz840400